within Pharmacolibrary.Drugs.ATC.S;

model S01BA14
  extends Pharmacokinetic.Models.PK_1C(
    weight         = 70,
    F              = 1,
    Cl             = 1.6666666666666667e-05,
    adminDuration  = 600,
    adminMass      = 0.5 / 1000000,   // mg → kg
    adminCount     = 1,
    Vd             = 0.001,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01
  );

  annotation (Documentation(
    info       = "<html><body><table><tr><td>Drug:</td><td>S01BA14</td></tr><td>route:</td><td>ophthalmic</td></tr><tr><td>n-compartments</td><td>1</td></tr></table><p>Loteprednol etabonate is a corticosteroid ophthalmic drug used to treat inflammation and pain in the eye caused by surgery, allergies, or other conditions. It is approved for ophthalmic use and is commonly used as eye drops today.</p><h4>Pharmacokinetics</h4><p>No published human systemic pharmacokinetic data found; estimated parameters for topical ophthalmic use in adults.</p><h4>References</h4><ol><li><p>Schopf, L, et al., &amp; Chen, H (2014). Ocular Pharmacokinetics of a Novel Loteprednol Etabonate 0.4% Ophthalmic Formulation. <i>Ophthalmology and therapy</i> 3(1-2) 63–72. DOI:<a href=&quot;https://doi.org/10.1007/s40123-014-0021-z&quot;>10.1007/s40123-014-0021-z</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/25134493/&quot;>https://pubmed.ncbi.nlm.nih.gov/25134493</a></p></li><li><p>Cavet, ME, et al., &amp; Phillips, E (2019). Rheological Properties, Dissolution Kinetics, and Ocular Pharmacokinetics of Loteprednol Etabonate (Submicron) Ophthalmic Gel 0.38. <i>Journal of ocular pharmacology and therapeutics : the official journal of the Association for Ocular Pharmacology and Therapeutics</i> 35(5) 291–300. DOI:<a href=&quot;https://doi.org/10.1089/jop.2018.0136&quot;>10.1089/jop.2018.0136</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/30907685/&quot;>https://pubmed.ncbi.nlm.nih.gov/30907685</a></p></li><li><p>Patel, N, et al., &amp; Sheth, N (2016). Development of loteprednol etabonate-loaded cationic nanoemulsified in-situ ophthalmic gel for sustained delivery and enhanced ocular bioavailability. <i>Drug delivery</i> 23(9) 3712–3723. DOI:<a href=&quot;https://doi.org/10.1080/10717544.2016.1223225&quot;>10.1080/10717544.2016.1223225</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/27689408/&quot;>https://pubmed.ncbi.nlm.nih.gov/27689408</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>"
  ));
end S01BA14;
